The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call reflects a ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Copenhagen, Denmark Saturday, August 9, 2025, 13:00 Hrs [IST] ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

The study involves several experimental treatment arms, each testing different combinations of epcoritamab with oral and intravenous drugs like lenalidomide, ibrutinib, and polatuzumab vedotin, ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...